CANCER:

Urothelial Cancer

Related cancers:

‹

›

BRCA2 mutation BRCA2 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - Today
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - Today
WDR5 overexpression WDR5 overexpression	Bladder Cancer Bladder Cancer	OICR-9429 Resistant: D – Preclinical J Exp Clin Cancer Res - 3 days
BRCA2 mutation BRCA2 mutation	Prostate Cancer Prostate Cancer	docetaxel Sensitive: C4 – Case Studies Orv Hetil - 4 days
No biomarker No biomarker	Prostate Cancer Prostate Cancer	177 Lu PSMA-617 Sensitive: B - Late Trials Novartis Press Release - 1 week
No biomarker No biomarker	Renal Cell Carcinoma RCC	nivolumab + cabozantinib tablet Sensitive: A1 - Approval Exelixis, Inc - 2 weeks
No biomarker No biomarker	Prostate Cancer Prostate Cancer	enzalutamide Sensitive: A1 - Approval PharmaTimes - 2 weeks
NECTIN4 expression NECTIN4 expression	Urothelial Cancer Urothelial Cancer	enfortumab vedotin Sensitive: C2 – Inclusion Criteria Clin Cancer Res - 2 weeks
TDO2 overexpression TDO2 overexpression	Bladder Cancer Bladder Cancer	cetuximab Resistant: C3 – Early Trials Cancer Rep (Hoboken) - 2 weeks
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline J Clin Oncol - 3 weeks
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	nivolumab Sensitive: B - Late Trials N Engl J Med - 3 weeks
CDKN2A mutation CDKN2A mutation	Urothelial Cancer Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Clin Cancer Res - 3 weeks
AR elevation AR elevation	Prostate Cancer Prostate Cancer	docetaxel Sensitive: C3 – Early Trials Eur J Cancer - 3 weeks
TLR4-L TLR4-L	Bladder Cancer Bladder Cancer	gemcitabine Sensitive: C3 – Early Trials Front Cell Dev Biol - 3 weeks
ATM underexpression ATM underexpression	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: D – Preclinical EACR 2021 - 3 weeks
BRCA1 underexpression BRCA1 underexpression	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: D – Preclinical EACR 2021 - 3 weeks
BRCA2 underexpression BRCA2 underexpression	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: D – Preclinical EACR 2021 - 3 weeks
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	apalutamide Sensitive: A1 - Approval
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	avelumab Sensitive: A1 - Approval
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Renal Cell Carcinoma RCC	avelumab + axitinib Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	histrelin acetate Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	cabazitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	avelumab + axitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	relugolix Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	sorafenib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	tivozanib Sensitive: A1 - Approval
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	mitomycin urothelial gel Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	temsirolimus Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	sunitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	everolimus + lenvatinib Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	docetaxel + prednisone Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	abiraterone acetate Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	everolimus Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	degarelix Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval
ATM mutation ATM mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	darolutamide Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	cabozantinib tablet Sensitive: A1 - Approval
No biomarker No biomarker	Bladder Cancer Bladder Cancer	cisplatin Sensitive: A1 - Approval
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	enfortumab vedotin Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	pembrolizumab + axitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	nivolumab Sensitive: A1 - Approval
FGFR2 mutation FGFR2 mutation	Urothelial Cancer Urothelial Cancer	erdafitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	nivolumab + ipilimumab Sensitive: A1 - Approval
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval
FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	erdafitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	axitinib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	pazopanib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	rucaparib Sensitive: A1 - Approval
BRCA2 mutation BRCA2 mutation	Prostate Cancer Prostate Cancer	rucaparib Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	aldesleukin Sensitive: A1 - Approval
HRD HRD	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	zoledronic acid Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	tislelizumab Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	toripalimab Sensitive: A1 - Approval
No biomarker No biomarker	Renal Cell Carcinoma RCC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	leuprolide mesylate injectable suspension Sensitive: A1 - Approval
No biomarker No biomarker	Bladder Cancer Bladder Cancer	EP Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Prostate Cancer Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Prostate Cancer Prostate Cancer	mitoxantrone Sensitive: A2 - Guideline
No biomarker No biomarker	Prostate Cancer Prostate Cancer	etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Prostate Cancer Prostate Cancer	atezolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Renal Cell Carcinoma RCC	bevacizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	atezolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Bladder Cancer Bladder Cancer	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Renal Cell Carcinoma RCC	bevacizumab + erlotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Renal Cell Carcinoma RCC	erlotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	carboplatin + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	5-fluorouracil + mitomycin Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	enfortumab vedotin Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	gemcitabine + paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	carboplatin + gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Bladder Cancer Bladder Cancer	cisplatin + gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Prostate Cancer Prostate Cancer	docetaxel Sensitive: A2 - Guideline
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	durvalumab Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	sunitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pazopanib Sensitive: A2 - Guideline
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	temsirolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	atezolizumab Sensitive: A2 - Guideline
CHEK2 mutation CHEK2 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline
CHEK1 mutation CHEK1 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline
AR splice variant 7 AR splice variant 7	Prostate Cancer Prostate Cancer	abiraterone acetate Resistant: A2 - Guideline
AR splice variant 7 AR splice variant 7	Prostate Cancer Prostate Cancer	enzalutamide Resistant: A2 - Guideline
RAD51B mutation RAD51B mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline
RAD51C mutation RAD51C mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline
RAD51D mutation RAD51D mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline
RAD54L mutation RAD54L mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

Urothelial Cancer

Associations(825)

Associations
(825)